The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Glioblastoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.
Some of the key takeaways from the Glioblastoma Pipeline Report:
Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years.
Glioblastoma companies working in the treatment market are Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others, are developing therapies for the Glioblastoma treatment
Emerging Glioblastoma therapies in the different phases of clinical trials are – Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others are expected to have a significant impact on the Glioblastoma market in the coming years.
In July 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, has announced results from the GBM-AGILE phase II/III study, which assessed paxalisib in comparison to the standard of care (SOC) for patients with glioblastoma, a severe form of brain cancer with a critical need for new treatments. The trial, registered under NCT03522298, aimed to address the urgent therapeutic gap for this life-threatening condition.
In July 2024, The Ivy Brain Tumor Center at Barrow Neurological Institute in the US has initiated dosing for the first participant in the Phase III Gliofocus clinical trial, which is evaluating niraparib, a selective PARP1/2 inhibitor, in adults with newly diagnosed MGMT-unmethylated glioblastoma. This open-label, randomized trial will compare the efficacy of niraparib against temozolomide, the current standard-of-care first-line chemotherapy. Supported by GSK, the trial will include 450 participants across more than 100 clinical sites in 11 countries.
In May 2024, Moleculin Biotech has announced the launch of an investigator-initiated Phase II NU 21C06 clinical trial, supported by funding from the National Institutes of Health (NIH), to evaluate WP1066 in combination with radiation therapy for adults with glioblastoma.
In February 2024, The Institute of Cancer Research (ICR) in London has reported encouraging results from a Phase I/II clinical trial of 2-OHOA, a new drug derived from oleic acid, for the treatment of glioblastoma. Oleic acid, found naturally in animal and vegetable fats like olive oil, is the basis for 2-OHOA, a synthetic lipid designed to inhibit cancer cell growth by restructuring their abnormal membranes.
Glioblastoma Overview
Glioblastoma, also known as glioblastoma multiforme (GBM), is a type of malignant brain tumor that arises from astrocytes, a type of supportive cells in the brain. It is the most aggressive and common form of primary brain cancer in adults. Glioblastomas are highly infiltrative tumors, meaning they spread rapidly and invade surrounding brain tissue, making complete surgical removal difficult.
Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight
Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:
Enzastaurin: Denovo BioPharma
Asunercept: Apogenix
Azeliragon: Cantex
VXM01: VAXIMM
MB-101: Mustang Bio
JIN 001: J INTS BIO
CT 179: Curtana Pharmaceuticals
PRT3645: Prelude Therapeutics
CD200AR L: OX2 Therapeutics
ADI-PEG 20: Polaris Group
CM93: Crimson Biopharm
Berubicin: CNS Pharmaceuticals
SurVaxM: MimiVax
BPM31510: Berg, LLC
ASC40: Ascletis
Enzastaurin: Denovo Biopharma
Marizomib: Celgene Corporation
Glioblastoma Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Glioblastoma Molecule Type
Glioblastoma Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Glioblastoma Pipeline Therapeutics Assessment
Glioblastoma Assessment by Product Type
Glioblastoma By Stage and Product Type
Glioblastoma Assessment by Route of Administration
Glioblastoma By Stage and Route of Administration
Glioblastoma Assessment by Molecule Type
Glioblastoma by Stage and Molecule Type
DelveInsight’s Glioblastoma Report covers around 200+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies
Some of the key companies in the Glioblastoma Therapeutics Market include:
Key companies developing therapies for Glioblastoma are – Array Biopharma, AstraZeneca, Doule bond Pharmaceuticals, Philogen, Immatics N.V, BioNTech, InovioPharma, Noxxon Pharma, Celgene Corporation, Karyo Pharma, Neugate Theranostics, Novartis, Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, Oncotelic Therapeutics, Autotelic Therapeutics, ACADIA Pharmaceuticals, Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis, 3-V Biosciences, Yumanity Therapeutics, and others.
Glioblastoma Pipeline Analysis:
The Glioblastoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Glioblastoma drugs and therapies
Glioblastoma Pipeline Market Drivers
Rising incidence of Glioblastoma multiforme, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Glioblastoma Market.
Glioblastoma Pipeline Market Barriers
However, aggressive nature of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Glioblastoma Market growth.
Scope of Glioblastoma Pipeline Drug Insight
Coverage: Global
Key Glioblastoma Companies: Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others
Key Glioblastoma Therapies: Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others
Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers
Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials
Table of Contents
1. Glioblastoma Report Introduction
2. Glioblastoma Executive Summary
3. Glioblastoma Overview
4. Glioblastoma- Analytical Perspective In-depth Commercial Assessment
5. Glioblastoma Pipeline Therapeutics
6. Glioblastoma Late Stage Products (Phase II/III)
7. Glioblastoma Mid Stage Products (Phase II)
8. Glioblastoma Early Stage Products (Phase I)
9. Glioblastoma Preclinical Stage Products
10. Glioblastoma Therapeutics Assessment
11. Glioblastoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Glioblastoma Key Companies
14. Glioblastoma Key Products
15. Glioblastoma Unmet Needs
16 . Glioblastoma Market Drivers and Barriers
17. Glioblastoma Future Perspectives and Conclusion
18. Glioblastoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las vegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
